Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 58 peer-reviewed journal articles Updated
Vascular Surgery

Your Path Forward: Navigating a Buerger Disease Diagnosis

At a Glance

Buerger disease (TAO) is a rare inflammatory condition that blocks blood vessels in the hands and feet. The most critical step to prevent disease progression and avoid limb amputation is the complete cessation of all tobacco, nicotine, and cannabis products.

Receiving a diagnosis of Buerger disease can feel overwhelming and frightening. You may have heard that this condition can lead to limb loss, and it is natural to feel a sense of urgency or fear about the future. However, understanding the nature of this disease also reveals a clear path forward. Unlike many other vascular conditions, Buerger disease is highly responsive to the choices you make starting today. By focusing on the facts and the primary factor within your control, you can take an active role in stabilizing your health and protecting your limbs.

Understanding Buerger Disease

Buerger disease, also known as thromboangiitis obliterans (TAO), is a rare, non-atherosclerotic inflammatory condition [1][2]. This means it is not caused by the “clogging” of arteries from cholesterol (atherosclerosis), but rather by an intense inflammation of the small and medium-sized blood vessels in your hands and feet [3][4].

When these vessels become inflamed, they can develop thrombi (blood clots) that block the flow of oxygen-rich blood to your fingers and toes [3][5]. While the disease is serious, its global incidence has been decreasing over the last two decades [6][7]. It remains a rare condition that primarily affects younger individuals with a history of tobacco use [6][8].

The Power of Prevention: Complete Cessation

The single most important fact about Buerger disease is its absolute link to tobacco and cannabis use. These substances act as a “trigger” that fuels the inflammatory process in your vessels [9][10].

  • The Critical Factor: Complete and total cessation of all tobacco, nicotine, and cannabis products is the only proven way to stop the disease from progressing [11][12].
  • Why it Matters: Continued smoking (including marijuana) is the primary driver of disease flares and is strongly linked to the need for amputations [13][10].
  • Limb Salvage: Stopping the use of these triggers significantly improves the success of other treatments and is the most essential step in saving your limbs [14][15].

Three Stabilizing Facts for Your Recovery

While the diagnosis is serious, these three facts can help ground you as you begin your treatment journey:

  1. You Have a Direct Switch to Stop the Damage: Unlike many chronic diseases where the cause is unknown or uncontrollable, the “off switch” for Buerger disease activity is known: eliminating tobacco and cannabis [11][10]. If you stop using them entirely, the inflammatory process often halts, and your body can begin to heal or stabilize [14][15].
  2. Amputation is Not Inevitable: While statistics show that roughly 34% of patients may face amputation over 15 years, these figures are heavily weighted toward those who continue to smoke [13]. For those who quit immediately and permanently, the risk of losing a limb drops dramatically [16][1].
  3. Modern Interventions are Improving Outcomes: While cessation is the foundation, doctors now have more tools to help, including endovascular therapies (using thin tubes to clear blockages) and medications like iloprost that help open blood vessels and improve flow [15][17].

What to Avoid

Because Buerger disease is an inflammatory response to nicotine and inhaled smoke, “cutting back” is not enough. You must avoid:

  • Cigarettes, cigars, and pipes [13].
  • Cannabis and marijuana. Smoking marijuana carries the exact same risks for vessel inflammation as tobacco [10].
  • Chewing tobacco and snuff [13].
  • Vaping or e-cigarettes [18].
  • Nicotine replacement therapies (NRTs) like patches or gum, as nicotine itself may trigger the disease [18]. Note: Discuss non-nicotine medications like bupropion or varenicline with your doctor to assist with quitting [15].
  • Secondhand smoke whenever possible.

For more information, navigate through the rest of this guide:

01

Identifying the Symptoms of Buerger Disease

Learn to identify the early symptoms of Buerger disease. Understand warning signs like arch or hand pain, migrating red lumps, cold sensitivity, and rest pain.

02

The Biology of Buerger Disease: Why It’s Not Just "Clogged Arteries"

Understand the biology of Buerger disease (thromboangiitis obliterans). Learn how tobacco triggers vessel inflammation and how it differs from clogged arteries.

03

The Path to Diagnosis: Confirming Buerger Disease

Learn how Buerger disease is diagnosed. Understand the Shionoya criteria, bedside tests like the Allen test, and what corkscrew collaterals mean on a scan.

04

Managing Buerger Disease: Standard of Care and Beyond

Learn about Buerger disease treatment options, from mandatory smoking cessation and medications to surgical bypass and emerging stem cell therapies.

05

Building Your Care Team and Preparing for Your First Visit

Learn how to build a multidisciplinary care team for Buerger disease. Find out which specialists you need and how to prepare for your first appointment.

06

Limb Salvage and Long-Term Wellness with Buerger Disease

Learn how to manage Buerger disease for the long term. Discover daily self-care routines, monitoring schedules, and strategies for limb salvage and wellness.

Common questions in this guide

What causes Buerger disease?
Buerger disease is an intense inflammatory response in the blood vessels linked directly to tobacco and cannabis use. This inflammation causes blood clots to form, blocking oxygen-rich blood from reaching your fingers and toes.
Can I just cut back on smoking or use nicotine patches instead?
No, cutting back is not enough. You must completely stop all forms of tobacco, marijuana, vaping, and even nicotine replacement therapies like patches or gum, as nicotine itself can trigger the disease.
Will I need an amputation if I have Buerger disease?
Amputation is not inevitable. While the risk of limb loss is high for patients who continue to smoke, quitting all tobacco and cannabis products immediately and permanently drops this risk dramatically.
Are there any treatments to help blood flow in my limbs?
Yes, doctors can use endovascular therapies, which involve thin tubes to clear blockages, or prescribe medications like iloprost to help open up blood vessels and improve circulation in your limbs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How can you be certain this is Buerger disease rather than standard atherosclerosis or another form of vasculitis?
  2. 2.What is the current state of the blood flow in my limbs, and do I have any active ulcers or 'silent' blockages?
  3. 3.Can you recommend a smoking cessation program that specializes in the intense support needed for Buerger disease patients?
  4. 4.Are there any treatments, such as iloprost or endovascular procedures, that could help improve my circulation right now?
  5. 5.What signs of 'migrating phlebitis' or new symptoms should I watch for that indicate the disease is active?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Thromboangiitis obliterans (Buerger's disease).

    Rivera-Chavarría IJ, Brenes-Gutiérrez JD

    Annals of medicine and surgery (2012) 2016; (7()):79-82 doi:10.1016/j.amsu.2016.03.028.

    PMID: 27144003
  2. 2

    Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences.

    Fazeli B, Ligi D, Keramat S, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(10)) doi:10.3390/diagnostics11101736.

    PMID: 34679434
  3. 3

    Pathogenesis of thromboangiitis obliterans: Gene polymorphism and immunoregulation of human vascular endothelial cells.

    Sun XL, Law BY, de Seabra Rodrigues Dias IR, et al.

    Atherosclerosis 2017; (265()):258-265 doi:10.1016/j.atherosclerosis.2017.08.009.

    PMID: 28864202
  4. 4

    Long-term outcomes of large artery thromboangiitis obliterans and comparison with small artery thromboangiitis obliterans.

    Lee SA, Jeong MJ, Ko GY, et al.

    Medicine 2022; (101(1)):e28512 doi:10.1097/MD.0000000000028512.

    PMID: 35029910
  5. 5

    MiR-223 alleviates thrombus and inflammation in thromboangiitis obliterans rats by regulating NLRP3.

    Zhou H, Li CL, Xia PZ, He YX

    European review for medical and pharmacological sciences 2020; (24(20)):10605-10611 doi:10.26355/eurrev_202010_23418.

    PMID: 33155218
  6. 6

    The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study.

    Choi B, Jang SY, Kim SK, et al.

    Cardiovascular diagnosis and therapy 2020; (10(5)):1238-1244 doi:10.21037/cdt-20-582.

    PMID: 33224747
  7. 7

    Current Trends in Epidemiology and Clinical Features of Thromboangiitis Obliterans in Japan　- A Nationwide Survey Using the Medical Support System Database.

    Watanabe Y, Miyata T, Shigematsu K, et al.

    Circulation journal : official journal of the Japanese Circulation Society 2020; (84(10)):1786-1796 doi:10.1253/circj.CJ-19-1165.

    PMID: 32879220
  8. 8

    Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research.

    Li MD, Wang YF, Yang MW, et al.

    Current medicinal chemistry 2020; (27(35)):6057-6072 doi:10.2174/0929867326666190816233042.

    PMID: 31419926
  9. 9

    Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.

    Guo H, Sun L, Ling S, Xu JW

    Mediators of inflammation 2018; (2018()):7304096 doi:10.1155/2018/7304096.

    PMID: 30158835
  10. 10

    Serum heavy metal levels from tobacco smoke and Buerger's disease.

    Asadollahi Shahir AA, Khoshakhlagh AH, Mehrzad F, et al.

    Scientific reports 2025; (15(1)):40821 doi:10.1038/s41598-025-24542-2.

    PMID: 41258278
  11. 11

    Demographic Traits, Clinical Status, and Comorbidities of Patients With Thromboangiitis Obliterans in Japan.

    Watanabe Y, Shimizu Y, Hashimoto T, et al.

    Circulation journal : official journal of the Japanese Circulation Society 2024; (88(3)):319-328 doi:10.1253/circj.CJ-23-0211.

    PMID: 37423757
  12. 12

    Tetrahydrocannabinol vape-associated cannabis arteritis in a patient with minimal tobacco exposure.

    Colling M, Souri Y, Reifsnyder T

    Journal of vascular surgery cases and innovative techniques 2025; (11(1)):101673 doi:10.1016/j.jvscit.2024.101673.

    PMID: 39691796
  13. 13

    Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.

    Le Joncour A, Soudet S, Dupont A, et al.

    Journal of the American Heart Association 2018; (7(23)):e010677 doi:10.1161/JAHA.118.010677.

    PMID: 30571594
  14. 14

    An Unusual Case of Thromboangiitis Obliterans With Concurrent Deep Vein Thrombosis and Pulmonary Embolism.

    Vaezi Z, Baker DL

    Cureus 2025; (17(11)):e96506 doi:10.7759/cureus.96506.

    PMID: 41384188
  15. 15

    The Effect of Smoking Cessation on the Technical Success of Endovascular Treatment for Thromboangiitis Obliterans.

    Gundogmus CA, Samadli V, Sorkun M, Oguzkurt L

    Journal of vascular and interventional radiology : JVIR 2023; (34(6)):1038-1044 doi:10.1016/j.jvir.2023.02.008.

    PMID: 36791958
  16. 16

    Predictors of Reamputation in Patients With Advanced-Stage Thromboangiitis Obliterans Ulcers: A Retrospective Cohort Study.

    Önaloğlu Y, Gümüş ÖF, Karakılıç B, et al.

    International wound journal 2026; (23(2)):e70853 doi:10.1111/iwj.70853.

    PMID: 41708155
  17. 17

    Outcomes of endovascular treatment versus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans.

    Lee CY, Choi K, Kwon H, et al.

    PloS one 2018; (13(10)):e0205305 doi:10.1371/journal.pone.0205305.

    PMID: 30300407
  18. 18

    Toll-like receptor signaling pathway involved in pathogenesis of thromboangiitis obliterans through activating of NF-κB.

    Guo F, Bi Y, Yin J, Guo Y

    Clinics (Sao Paulo, Brazil) 2024; (79()):100357 doi:10.1016/j.clinsp.2024.100357.

    PMID: 38640750

This page provides educational information about a Buerger disease diagnosis. It is not a substitute for professional medical advice, and you should always consult your vascular specialist regarding treatment and smoking cessation.

Get notified when new evidence is published on Buerger disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.